[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646263":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":40,"locations":49,"responsibleParty":67,"collaborators":31,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":31,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":31,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":31,"overallStatus":88,"whyStopped":31,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group A","EXPERIMENTAL","SHR-8068+ Adebrelimab+ Bevacizumab +Transarterial Chemoembolization(TACE)",[13],"Drug: SHR-8068+ Adebrelimab+ Bevacizumab",{"label":15,"type":16,"description":17,"interventionNames":18},"Treatment group B","ACTIVE_COMPARATOR","SHR-8068 Placebo+ Adebrelimab Placebo+ Bevacizumab Placebo+Transarterial Chemoembolization(TACE)",[19],"Drug: SHR-8068 Placebo+ Adebrelimab Placebo+ Bevacizumab Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Treatment group C","SHR-8068 Placebo+Adebrelimab+ Bevacizumab +Transarterial Chemoembolization(TACE)",[24],"Drug: SHR-8068 Placebo +Adebrelimab+ Bevacizumab",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","SHR-8068+ Adebrelimab+ Bevacizumab","SHR-8068+ Adebrelimab+ Bevacizumab,intravenous infusion，Transarterial Chemoembolization(TACE)",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"SHR-8068 Placebo+ Adebrelimab Placebo+ Bevacizumab Placebo","SHR-8068 Placebo+ Adebrelimab Placebo+ Bevacizumab Placebo,intravenous infusion，Transarterial Chemoembolization(TACE)",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"SHR-8068 Placebo +Adebrelimab+ Bevacizumab","SHR-8068 Placebo +Adebrelimab+ Bevacizumab,intravenous infusion，Transarterial Chemoembolization(TACE)",[21],[41,46],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},"Junqin Yang","CONTACT","+86-0518-82342973","junqin.yang@hengrui.com",{"name":47,"role":43,"phone":44,"phoneExt":31,"email":48},"Huan Wang","huan.wang.hw396@hengrui.com",[50],{"facility":51,"status":31,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Zhongshan Hospital，Fudan University","Shanghai","Shanghai Municipality","200032","China","CN",{"type":58,"coordinates":59},"Point",[60,61],121.45806,31.22222,{"lat":61,"lon":60},[64],{"name":65,"role":66,"phone":31,"phoneExt":31,"email":31},"Jia Fan","PRINCIPAL_INVESTIGATOR",{"type":68,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100646263","phase-3-a-study-of-tace-in-combination-with-shr-8068-adebrelimab-and-bevacizumab-versus-tace-in-participants-with-incurable-hepatocellular-carcinoma-100646263",false,"NCT07691762","A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma","A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age 18-75 years old, male or female;\n2. Diagnosis confirmed HCC by pathologically or clinically;\n3. At least one measurable lesion;\n4. Child-Pugh liver function grade A;\n5. ECOG-PS score: 0 or 1;\n6. Eligible for TACE treatment as assessed by the investigator;\n7. Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period;\n8. Consent to contraception\n\nExclusion Criteria:\n\n1. Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma \u002F hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;\n2. Participants with any active, known or suspected autoimmune disorder;\n3. Participants with hypertension which cannot be well controlled by antihypertensives;\n4. Uncontrolled cardiac diseases or symptoms;\n5. Participants with hepatic encephalopathy;\n6. Prior esophageal and\u002For gastric varices bleeding within 6 months prior to initiation of study treatment\n7. History of gastrointestinal perforation and\u002For fistula,\n8. Participants with other potential factors that may affect the study results.","ALL","18 Years","75 Years",{"count":80,"type":81},690,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.\n\nParticipants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.",[87],"Hepatocellular Carcinoma","NOT_YET_RECRUITING","2026-07-02",{"date":91,"type":92},"2026-07-09","ACTUAL",{"date":94,"type":81},"2026-07",{"date":96,"type":81},"2031-04",{"name":5,"class":6},1]